Sinusoidal obstruction syndrome medical therapy
|
Sinusoidal obstruction syndrome Microchapters |
|
Differentiating Sinusoidal obstruction syndrome from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Sinusoidal obstruction syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Sinusoidal obstruction syndrome medical therapy |
|
Directions to Hospitals Treating Sinusoidal obstruction syndrome |
|
Risk calculators and risk factors for Sinusoidal obstruction syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
The management of sinusoidal obstruction syndrome depends on the severity of the disease. However, supportive care is the mainstay of therapy for mild and moderate sinusoidal obstruction syndrome. The severe form of sinusoidal obstruction syndrome needs defibrotide (thrombolytic agent) along with supportive care. Patients are advised to avoid supplements and medications that are linked to hepatic injury.
Medical Therapy
- The management of sinusoidal obstruction syndrome depends on the severity of the disease.[1]
- Supportive care is the mainstay of treatment.[2]
- Supportive measures include:
- Maintaining intravascular volume
- Avoidance of hepatotoxic agents
- Paracentesis can be done to remove ascitic fluid
- Narcotics can be used to keep patient pain free.
- Patients with mild to moderate sinusoidal obstruction syndrome can be treated with supportive care alone. However, severe cases need defibrotide (thrombolytic agent) along with supportive care.[3][4]
| Parameters | Mild | Moderate | Severe |
|---|---|---|---|
| Serum total bilirubin |
|
|
|
| Serum aspartate aminotransferase (AST) |
|
|
|
| Weight above baseline |
|
|
|
| Serum creatinine |
|
|
|
| Rate of change | Slow (over 6–7 d) | (over 4–5 d) | Rapid (over2–3 d) |
References
- ↑ Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T (2000). "Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study". Br. J. Haematol. 111 (4): 1122–9. PMID 11167751.
- ↑ Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC (1998). "Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population". Blood. 92 (3): 737–44. PMID 9680339.
- ↑ Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC (2002). "Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome". Blood. 100 (13): 4337–43. doi:10.1182/blood-2002-04-1216. PMID 12393437.
- ↑ Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, Straham B, Gross-Wieltsch U, Sykora KW, Ridolfi-Lüthy A, Basu O, Gruhn B, Güngör T, Mihatsch W, Schulz AS, Strahm B (2004). "Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention". Bone Marrow Transplant. 33 (2): 189–95. doi:10.1038/sj.bmt.1704329. PMID 14661036.